Ridner Sheila H, Dietrich Mary S
Vanderbilt University School of Nursing, 461 21st Avenue South, Godchaux Hall, Nashville, TN, 37240, USA,
Support Care Cancer. 2015 Oct;23(10):3103-12. doi: 10.1007/s00520-015-2684-y. Epub 2015 Mar 10.
The purpose of this instrument development project was to create a self-report tool to evaluate arm lymphedema and associated symptoms in breast cancer survivors.
The Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A) was developed and tested in three phases: phase 1-literature review and expert panel; phase 2-preliminary validation; and phase 3-final validation.
Phase 1: The most common symptoms experienced by breast cancer survivors with lymphedema were identified. A 52-item scale was developed. Phase 2: 128 community-dwelling breast cancer survivors (64 with lymphedema, 64 without lymphedema) completed the LSIDS-A. Feedback from the participants was that the format was "clear" and "made sense"; therefore, the response structure was left intact. Sixteen items were deleted leaving a 36-item revised instrument. Phase 3: Subsequent testing in a total sample of 236 breast cancer survivors with lymphedema was undertaken. The Cronbach's alpha reliability values for the overall intensity and distress scores were 0.93 and 0.94, respectively. The Kuder-Richardson values ranged from 0.66 to 0.92. Divergent validity evaluated against Marlowe-Crowne Social Desirebility Scale overall was acceptable (intensity, r s = 0.08; distress, r s = -0.12). Convergent validity was acceptable as tested with multiple instruments (e.g., Functional Assessment of Cancer Therapy-Breast +4, overall intensity r s = -0.44, overall distress r s = -.48) CONCLUSIONS: The 30-item LSIDS-A is a valid and reliable instrument that can be used to assess arm lymphedema and its associated symptoms.
本仪器开发项目的目的是创建一种自我报告工具，以评估乳腺癌幸存者的手臂淋巴水肿及相关症状。
淋巴水肿症状强度与困扰调查-手臂版（LSIDS-A）分三个阶段进行开发和测试：第1阶段-文献综述和专家小组；第2阶段-初步验证；第3阶段-最终验证。
第1阶段：确定了患有淋巴水肿的乳腺癌幸存者最常见的症状。编制了一个包含52个条目的量表。第2阶段：128名社区居住的乳腺癌幸存者（64名有淋巴水肿，64名无淋巴水肿）完成了LSIDS-A。参与者的反馈是，该量表的形式“清晰”且“合理”；因此，响应结构保持不变。删除了16个条目，留下一个包含36个条目的修订版工具。第3阶段：随后对总共236名患有淋巴水肿的乳腺癌幸存者进行了测试。总体强度和困扰评分的克朗巴哈系数可靠性值分别为0.93和0.94。库德-理查森值范围为0.66至0.92。与马洛-克劳恩社会期望量表相比，总体发散效度是可接受的（强度，rs = 0.08；困扰，rs = -0.12）。经多种工具测试，收敛效度是可接受的（例如，癌症治疗功能评估-乳腺癌+4，总体强度rs = -0.44，总体困扰rs = -0.48）结论：包含30个条目的LSIDS-A是一种有效且可靠的工具，可用于评估手臂淋巴水肿及其相关症状。
